The co-inventor of the groundbreaking gene editing technology talks to OneZero about a world where illness could be diagnosed in minutes.
Category: biotech/medical – Page 2,148
We sought to determine whether pre-eclampsia, spontaneous preterm birth or the delivery of infants who are small for gestational age were associated with the presence of bacterial DNA in the human placenta. Here we show that there was no evidence for the presence of bacteria in the large majority of placental samples, from both complicated and uncomplicated pregnancies. Almost all signals were related either to the acquisition of bacteria during labour and delivery, or to contamination of laboratory reagents with bacterial DNA. The exception was Streptococcus agalactiae (group B Streptococcus), for which non-contaminant signals were detected in approximately 5% of samples collected before the onset of labour. We conclude that bacterial infection of the placenta is not a common cause of adverse pregnancy outcome and that the human placenta does not have a microbiome, but it does represent a potential site of perinatal acquisition of S. agalactiae, a major cause of neonatal sepsis.
In the premiere of the HBO/BBC miniseries Years and Years, two parents are worried. Their teenage daughter Bethany has been hiding behind a 3D animated emoji mask and has scheduled a talk with them. Trying to figure out what they’re up against, they sneak a peek at her internet searches. When they discover that she’s been searching for information about being trans, they’re relieved; they can handle a transgender child.
Except when it comes time for their talk, Bethany tells her parents she’s transhuman and that she wants to “live forever as information.” The show represents transhumanist technology and aspirations, many of which revolve around upgrading and digitizing the human body, as a movement that will bring positive, negative, and downright confusing implications, ultimately changing the human race. The real question is what exactly that means. Humans opened the Pandora’s box of merging technology and biology a long time ago, and we’re now speeding head-on into the consequences, despite not knowing what humanity will become.
Bethany’s “coming out” scene hinges on the fact that the changes she desires are far more dangerous—and, for her parents, far more difficult to stomach—than gender reassignment. Bethany’s excitement at escaping the mortal coil brims with typical teenage naïveté: “Transhumans are not male or female, but better,” she tells her parents. For Bethany, that means no longer being human. “I will be data!” she enthuses.
New video from our 2019 Undoing Aging conference: Mikhail Shchepinov, Chief Science Officer at Retrotope, Inc., on aging and diseases resulting from the gradual accumulation of oxidative damages. undoing-aging.org/videos/mikhail-shchepinov-presenting-at-undoing-aging-2019 ____________
Posted in biotech/medical, life extension, science
New video from our 2019 Undoing Aging conference: Mikhail Shchepinov, Chief Science Officer at Retrotope, Inc., on aging and diseases resulting from the gradual accumulation of oxidative damages.
undoing-aging.org/videos/mikhail-shchepinov-presenting-at-undoing-aging-2019
____________
Candida auris, an invisible fungus, can live on surfaces for weeks. It affects people with weakened immune systems, often when they’re at hospitals.
For the first time, a government is supporting a plan to create animal embryos with human cells and bring them to term, resulting in a type of humanimal known as a human-animal chimera.
According to Nature, a committee from Japan’s science ministry signed off on a request by researchers to grow human pancreases in either rats or mice, the first such experiment to gain approval since a government ban was reversed earlier this year.
Sciatic nerves isolated from untreated mice (left) show evidence of demyelination, which is improved upon treatment (right)
Researchers in Canada and Sweden have used a novel Crispr system to reverse harm caused by muscular dystrophy – usually thought to be permanent – in mice. Pre-clinical studies often treat animals early, before symptoms can be detected, says Ronald Cohn, senior scientist, president and chief executive officer of The Hospital for Sick Children in Toronto.
‘Our results now show that the therapeutic window may indeed be wider,’ Cohn tells Chemistry World. This is significant as all patients ‘are currently diagnosed at a time when symptoms are already presenting’, he adds. The researchers are now exploring partnerships with industry to work towards bringing the research into a clinical trial.
Physicists from Nanyang Technological University, Singapore (NTU Singapore) and the Niels Bohr Institute in Copenhagen, Denmark, have devised a method to turn a non-magnetic metal into a magnet using laser light.
Magnets and their magnetic field are typically produced by circulating currents, like those found in everyday electromagnetic coils. The ‘handedness’ of these coils—whether they are wound in clockwise or anticlockwise fashion—determines the direction of the magnetic field produced.
The scientists theorise that when non-magnetic metallic disks are illuminated by linearly polarised light—light that does not possess any handedness of its own—circulating electric currents and hence magnetism can spontaneously emerge in the disk.
Researchers are still optimistic about finding disease-altering medicines—just not anytime soon.
- By Karen Weintraub on July 18, 2019
For the past quarter century, scientists battled Alzheimer’s disease under a single guiding principle: that protein clumps—beta-amyloid—deposited outside sensitive brain cells gradually damage neuronal functions and trigger memory loss. The solution seems simple: remove junk amyloid, protect the brain.
They could be completely wrong.
Last month, Alzheimer’s disease defeated another promising near-market drug that tried to prevent or remove amyloid deposits, adding to the disease’s therapeutic “graveyard of dreams.” Although the drug removed toxic amyloid, the patients didn’t get better. The failure is once again spurring scientists to confront an uncomfortable truth: targeting amyloid clumps when patients already show memory symptoms doesn’t work. Wiping out soluble amyloid—fragments of proteins before they aggregate into junk—also dead ends.